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Abstract
In complex diseases, various combinations of genomic perturbations often lead to the same phenotype. On a molecular
level, combinations of genomic perturbations are assumed to dys-regulate the same cellular pathways. Such a pathway-
centric perspective is fundamental to understanding the mechanisms of complex diseases and the identification of
potential drug targets. In order to provide an integrated perspective on complex disease mechanisms, we developed a
novel computational method to simultaneously identify causal genes and dys-regulated pathways. First, we identified a
representative set of genes that are differentially expressed in cancer compared to non-tumor control cases. Assuming that
disease-associated gene expression changes are caused by genomic alterations, we determined potential paths from such
genomic causes to target genes through a network of molecular interactions. Applying our method to sets of genomic
alterations and gene expression profiles of 158 Glioblastoma multiforme (GBM) patients we uncovered candidate causal
genes and causal paths that are potentially responsible for the altered expression of disease genes. We discovered a set of
putative causal genes that potentially play a role in the disease. Combining an expression Quantitative Trait Loci (eQTL)
analysis with pathway information, our approach allowed us not only to identify potential causal genes but also to find
intermediate nodes and pathways mediating the information flow between causal and target genes. Our results indicate
that different genomic perturbations indeed dys-regulate the same functional pathways, supporting a pathway-centric
perspective of cancer. While copy number alterations and gene expression data of glioblastoma patients provided
opportunities to test our approach, our method can be applied to any disease system where genetic variations play a
fundamental causal role.
Citation: Kim Y-A, Wuchty S, Przytycka TM (2011) Identifying Causal Genes and Dysregulated Pathways in Complex Diseases. PLoS Comput Biol 7(3): e1001095.
doi:10.1371/journal.pcbi.1001095
Editor: Markus W. Covert, Stanford University, United States of America
Received May 12, 2010; Accepted January 28, 2011; Published March 3, 2011
This is an open-access article distributed under the terms of the Creative Commons Public Domain declaration which stipulates that, once placed in the public
domain, this work may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose.
Funding: This work was supported by the Intramural Research Program of the National Institutes of Health, the National Library of Medicine, and by the National
Institutes of Health. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: przytyck@ncbi.nlm.nih.gov
Introduction
Complex diseases are typically caused by combinations of
molecular perturbations that might vary stronglyindifferent patients,
yet dys-regulate the same component of a cellular system [1]. In
recent years, whole-genome gene expression sets have increasingly
been used to search for markers, allowing an improved diagnosis of
diseases or classification of their subtypes [2,3,4,5,6,7,8]. Several
approaches combined expression measurements with various types of
direct or indirect pathway information, leading to improved disease
classification [9,10,11,12], prioritization of disease associated genes
[13,14,15] and identification of disease specific dysregulated path-
ways [16]. Furthermore, considerable efforts towards integrated
approaches for uncovering disease causing genes [17,18] and
elucidation of relations between variability in gene expression and
genotype [19] have recently been made. In particular, Tu et al.
developed a random walk approach to infer regulatory pathways
[13,14,20] in yeast. Suthram et al. [21] further improved this
approach by using the analogy between random walks and current
flow in electric circuits. Recently, Yeger-Lotem et al. developed a
min-cost flow based algorithm, uncovering cellular pathways that are
implicated in several neurodegenerative disorders [22].
Studying associations between individual disease genes and
genotype alterations allowed us to uncover potential causative
factors and affected molecular entities. While previous methods
provided valuable insights into the modular nature of diseases by
elucidating groups of differentially expressed genes, the flow of
information from potential causes to effected genes in the
molecular interaction network hasn’t been investigated. In this
paper, we present a genome-wide approach to simultaneously
determine dys-regulated pathways and their putative causes/
factors. We utilized gene expression and genomic alteration
profiles of 158 glioblastoma multiforme (GBM) patients. We
started by selecting a set of differentially expressed target genes,
and then identified pathways connecting genes that are located in
areas of genomic alterations. Then, we selected target genes,
choosing pathways that are likely to explain the expression
abnormalities of target genes. Consistent with the general strategy
of eQTL analysis, we assumed that expression variations of the
target genes are, at least in part, caused by genomic alterations.
Specifically, we first used association analysis to identify possible
cause-target gene pairs. Then, we modeled the propagation of
information from a potentially causal gene to a target gene as the
flow of electric current through a network of molecular
interactions. To assess the significance of identified pathways we
carefully designed a permutation test. Finally, we used a graph-
theoretical approach to further narrow down the selected set of
putative causal genes. We validated our approach by testing the
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disease genes and literature searches. We also examined the
subnetworks, connecting causal and target genes and identified
cancer hub genes and sets of functionally related genes which
indicate involvement of specific cellular pathways. Among these
pathways we found several expected key players such as EGFR
and Insulin Receptor signaling pathways, RAS signaling, as well as
a glioma-associated regulation of transforming growth factor-b2
production and SMAD pathway. Importantly, such pathways can
be considered as ‘‘GO biological process hubs’’ or ‘‘highways’’,
connecting many different causal genes with their targets. Such an
observation supports the hypothesis that many different genomic
alterations potentially dys-regulate the same pathways in complex
diseases. In addition, we analyzed the global properties of
identified associations and found a cluster of causal/disease gene
activities on chromosomes that are strongly affected by genomic
alterations. Such results allowed us to identify candidate causal
genes for prominent signaling and regulation proteins that
putatively play a role in GBM. Comparing our method to a basic
genome-wide association approach, we demonstrated the in-
creased predictive power of our model.
Results
Outline of the Method
We developed a novel computational method to identify causal
genes and associated dys-regulated pathways by an integration of
several layers of data, including profiles of gene expression and
genomic alterations (Fig. 1). Specifically, we assembled an
interaction network, utilizing molecular interaction data such as
protein-protein interactions, phosphorylation events and protein-
transcription factor interactions. Briefly, our algorithm consists of
four main steps (Figures 1A–D): (i) selection of a set of differentially
expressed target genes, (ii) identification of possible causal loci of
each target gene by an eQTL-analysis, (iii) identification of a set of
putative causal genes by determining pathways between causal
and target genes through the network of molecular interactions,
and (iv) determination of a subset of causal genes that best explain
the underlying disease cases. In the following, we present a more
detailed description of these four steps. Further details are
described in the corresponding sections of Materials & Methods.
Selecting Target Genes in GBMs
Since a complex disease may manifest itself differently in
patients, we first developed a method that selects a set of genes that
are differentially expressed in the disease cases and cover
individual patient alterations. To identify such representative
genes, we modeled the selection of target genes as a multi-set cover
problem (Fig. 1A). Specifically, we determined a set of genes that
were differentially expressed in 158 glioblastoma cases compared
to 32 non-tumor control cases (see selection of target genes section
in Materials & Methods). We defined that a differentially
expressed gene covers a particular disease case if the gene was
differentially expressed in the underlying case. Clearly, genes that
cover many cases are expected to represent genes and pathways
commonly dys-regulated in the disease. To capture disease
heterogeneities we also demanded that each disease case was
covered by at least a certain number of target genes, a key
parameter of our approach. Intuitively, with very small coverage
we can identify only the most commonly differentially expressed
genes. By increasing coverage we can capture genes that are
specific to smaller subgroups of patients. Thus, we required a
certain level of coverage and simultaneously demanded that each
gene covers as many cases as possible. To achieve this goal, we
formulated the problem as a minimum multi-set cover (see
selection of target genes section in Materials & Methods) and
solved it using a greedy algorithm. We tested several combinations
of coverage and the number of outliers (a second, less prominent
parameter of the algorithm) and observed that obtained gene sets
strongly overlapped, demonstrating the robustness of our ap-
proach (see Text S1 for details of the algorithm and parameter
settings). Demanding coverage of 55 and allowing 3 outliers, we
selected 74 target genes as presented in Fig. 2 (see Table S1 for an
annotated list of target genes).
Association between Gene Expression and Copy Number
Alterations
The goal of this step is to identify an initial set of possible
associations between copy number variations and target genes for
further analysis (Fig. 1B). Since genomic variations in neighbor-
ing regions tend to be highly correlated, we first chose a subset
of 911 representative loci (i.e. tag loci), significantly lowering
computational costs (see eQTL mapping section in Materials and
Methods). We observed that the number of genes that a tag locus
can harbor varied strongly and found on average 27 genes per
tag locus. Applying a standard eQTL approach [19,23] we
performed a linear regression analysis, allowing us to determine
genome-wide associations between the expression of target genes
and copy number alterations of tag loci. Specifically, we
calculated p-values for each gene-locus pair under the null
hypothesis that the slope of the linear regression is 0. This way we
selected, for further analysis, 3,091 associated gene-locus pairs
(p,0.01), amounting to ,5% of all 67,414 (911674) tested pairs.
On average, we selected 41 associated tag loci per target gene,
while 776 tag loci had at least one target gene (see Text S1 for
algorithmic details).
Author Summary
It is now being recognized that complex diseases should
be studied from the perspective of dys-regulated path-
ways and processes rather than individual genes. Indeed,
various combinations of molecular perturbations might
lead to the same disease. In such cases, responses to these
perturbations are expected to converge to common
pathways. In addition, signals that are associated with
each individual perturbation might be weak, rendering
studies of complex diseases particularly challenging.
Aiming to provide an integrated perspective on complex
disease mechanisms we developed a novel computational
method to simultaneously identify causal genes and dys-
regulated pathways. Starting with an identification of a
disease-associated set of genes and their statistical
associations with genomic alterations, we utilized graph-
theoretical techniques and combinatorial algorithms to
determine potential paths from the genomic causes
through a network of molecular interactions. We applied
our method to sets of genomic alterations and gene
expression profiles of Glioblastoma multiforme (GBM)
patients, uncovering candidate causal genes and causal
paths that are potentially responsible for the altered
expression of disease associated target genes. While copy
number alterations and gene expression data of GBM
patients provided opportunities to test our approach, our
method can be applied to any disease system where
genetic alterations play a fundamental causal role, and
provides an important step toward the understanding of
complex diseases.
Dysregulated Pathways in Complex Diseases
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The relatively liberal p-value threshold used in the previous step
allowed us to retain most of potentially interesting relationships.
Although this step filtered out the least promising pairs, a large
number of false positives are expected to pass this threshold.
Reducing false discovery rate by simply decreasing the p-value
threshold would retain extremely well correlated loci-target gene
pairs only, therefore missing a large spectrum of potentially
interesting pairs. In fact, the correlation between copy number
variation in the causal gene and the gene expression of its target
gene doesn’t have to be strong since such a signal might have been
affected by varying degradation rates and posttranslational
modifications. Furthermore, genotypic alterations in several loci
might lead to the dys-regulation of the same pathway and
therefore changing the expression of a target gene in potentially
non-additive, epistatic ways. Since each genetically altered region
might harbor a large number of genes, we also aimed to identify
the most likely causal genes within each region.
In order to account for such effects we utilized protein-protein,
protein-DNA and phosphorylation networks (Fig. 1C). Existence
of statistically significant paths through an interaction network,
connecting putative causal and target genes not only provides
additional support for the relationship but also helps to identify
genes that participate in propagating the signal. This approach
also allows identifying the gene(s) within the altered regions
which were most likely the cause of the observed expression
changes of the selected target genes (Fig. 1C). Motivated by the
results of Suthram et al. [21], we adopted a variant of a circuit
flow algorithm and modeled the problem of finding a pathway
through an interaction network as current flow in an electric
circuit. We defined the conductance of each interaction as a
function of the expression correlation of the genes at the
endpoints of edges and the target gene. Such a model allows the
current to preferentially use interactions that more likely mediate
information from a causal to a target gene. Stipulating that only
transcription factors can change the expression of genes, we
Figure 1. Outline of our method. (A) We first selected target genes that were differentially expressed in disease cases, using a multi-set cover
approach. (B) In the second step, we detected genome-wide associations between gene expression changes of target genes and genomic
alterations, allowing us to find potential causal genomic areas. (C) In the third step, we determined causal paths from genomic alterations (i.e. causal
genes) to target genes by modeling and solving a current flow problem through a circuit of molecular interactions. (D) To select a final set of causal
genes, we designed a weighted multi-set cover algorithm. Constructing a bipartite graph between candidate causal genes and disease cases, we
labeled each edge with the associated set of target genes that were affected by the causal gene and were differentially expressed in the
corresponding disease case. In the final set-cover, causal genes in boxes covered each disease case with at least two target genes, allowing one
exception.
doi:10.1371/journal.pcbi.1001095.g001
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transcription factor and the target gene. The flow of current
from the target to its potential causal genes was computed by
solving a system of linear equations, allowing us to find a set of
candidate causal genes for each target gene. Importantly, we
considered edges corresponding to phosphorylation events and
protein-DNA interactions as directed, prompting a computa-
tional problem that theoretically can be tackled with a linear
programming approach [21]. However, the large size of the
underlying human interaction network imposed considerable
computational costs, prompting us to develop a heuristic that
preserved the directions of such molecular interactions. As a
null-model, we utilized a permutation test to estimate the
statistical significance of the current flow. After obtaining
empirical p-values we selected candidate causal genes for each
target gene if the empirical, gene specific p-value was ,0.05 (for
algorithmic details and parameter settings please see solution of
the electric circuit problem section in Materials & Methods and
Supplement Text S1). We obtained 1,763 pairs, consisting of 74
target and 701 potential causal genes that included a significant
number of GBM and glioma-specific genes (Table 1). Since we
identified associated gene-locus pairs with p,0.01 and found
target-causal gene pairs with p,0.05, all 1,763 pairs had an
estimated nominal p-value ,5610
24.
Final Causal Genes Explaining Disease Cases
While the electric circuit approach reduced the number of
putative causal genes significantly, the size of this gene set was still
considerably large. In the final step, we applied another filter by
considering two approaches – a statistical method and a hypothesis
driven optimization approach. In the statistical approach, we
accounted for multiple hypothesis testing and used a p-value cut-
off of 5610
28, producing 280 candidate causal genes. In the
optimization-based approach, we identified relevant causal genes
by selecting the set of genes that best explained all disease cases.
We defined that a putative causal gene explains a disease case if its
corresponding tag locus has a copy number alteration and its
affected target genes (i.e., genes sending a significant amount of
current to the causal gene) were differentially expressed in the
underlying disease case. In other words, if a link between a causal
gene and a disease case existed, we expected to observe both a
genomic alteration of a causal gene and differential expression of
its target gene in the same disease case. Since a causal gene may
potentially affect one or more target genes, we defined the weight of
the explanation as the number of such target genes. Therefore, a
gene that explained a disease by perturbing a larger number of
target genes had a higher weight, increasing the likelihood to be
chosen as a final causal gene (Fig. 1D). To choose a set of causal
genes explaining all cases except a few outliers with a minimum
Figure 2. Lists of selected target, causal and hub genes. Target and hub genes that are labeled red were up-regulated while genes labeled
green were down-regulated. Causal genes are marked in red (green) if they were found in amplified (deleted) genomic regions. We defined hubs as
genes that appeared in more than 10 causal pathways through the interaction network. Numbers in parentheses indicate the genes’ actual
occurrences.
doi:10.1371/journal.pcbi.1001095.g002
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the minimum weighted multi-set cover problem (please see selecting a final
set of causal genes section in Materials & Methods and Text S1 for
algorithmic details). Utilizing a greedy algorithm, we determined a
set of 128 putative, final causal genes that were involved in 625
causal and target gene pairs. Using a permutation test, we found
that the random selection of a gene set of at most this size occurred
with p,3.1610
24.
Validation
In the following, we provide a quantitative validation of the set
of putative causal genes, pathway hubs and target genes. Where
applicable, we also compared our results to previous approaches.
Subsequently, we established the robustness of our method with
respect to parameter settings. Finally, we analyzed individual
genes and pathways.
To assess the significance of our set of causal genes, we
determined the overlap with sets of GBM/glioma specific genes.
In particular, AceView [24] provided a list of 93 GBM specific
genes. In the first step of the algorithm, we determined associations
between copy number variations and expression of target genes,
yielding 16,056 associated genes that had a large, but statistically
insignificant overlap with the set of glioblastoma specific genes
(p,0.56, Table 1). The application of the electric circuit algorithm
reduced this set to 701 candidate causal genes with a significant
enrichment of 10 GBM specific and 25 Glioma related genes
(p,0.05, Table 1). We also checked the advantage of using the
current flow approach instead of simply selecting pairs based on
more stringent p-value cut-offs. Namely, given our eQTL results,
we used a Bonferroni-corrected threshold of 1.5610
27, providing
24 pairs between 4 target genes and 22 loci that harbor a total of
1,026 genes, including 12 GBM relevant genes from AceView
(p,0.003, Table 1). However, this approach failed to find any
significant associations for most of the target genes. For the 4
target genes, we obtained a rather big set of candidate causal
genes, which was not enriched with glioma genes in DAVID.
Next, we focused on the last step of the algorithm. As a result of
the current flow step we obtained 1,763 pairs with a nominal p-
value ,5610
24, involving 701 causal genes. Using the weighted
set cover approach, we identified 128 causal genes that harbored 6
GBM relevant genes (Table 1). Specifically, we found that both
sets shared CDKN2A, EGFR, ERBB4, PTEN, RB1 and TP53
(p,4.7610
24). Utilizing a set of glioma relevant genes from
DAVID database [25,26], we obtained consistent results (Table 1).
In contrast, by Bonferroni-correcting causal-target gene pairs we
obtained 280 causal genes, including only 4 GBM related genes
according to AceView (p,0.17, Table 1).
To test an alternative approach, we greedily chose loci with
smallest p-values until we pooled at least 128 putative causal genes.
The obtained set of putative causal genes included only 2 GBM
genes (p,0.3), suggesting that the current flow algorithm and the
subsequent filtering step with a set-cover allowed us to uncover
more cancer relevant genes than the simple association approach.
Focusing on the final set of 128 causal genes, we utilized
canonical pathway data from DAVID and found that the final set
of 128 causal genes was significantly enriched with glioma, cell
cycle genes, p53 signaling pathway and proteasomal genes
(p,0.05). In Table 2 we listed the most enriched annotated
pathways, their genes and p-values. The complete list of 128 final
causal genes is shown in Fig. 2, and an annotated list is provided in
Table S2.
We also assessed the importance of genes in the paths from
putative causal genes to their target genes. As described in
identifying dysregulated pathways section in Materials &Methods,
we identified causal paths between a target and a causal gene by
finding a maximum current path through the network of
molecular interactions. In particular, we demanded that the genes
in causal paths have significant p-values while the current passing
through all genes in the path is maximized (please see identifying
dysregulated pathways section in Materials & Methods and also
Text S1 for algorithmic details), allowing us to identify 461 genes
in 995 interactions. Using a threshold of more than 10 occurrences
in causal paths (corresponding to 20% of most frequently
appearing genes), we observed the emergence of hubs, genes that
appeared in a disproportionally large number of pathways (Fig. 2).
Such a set of hubs contained important transcription factors such
as MYC and E2F1 and oncogenes such as JUN and RELA and
was enriched with genes that appeared in cancer pathways
(p,2.2610
28), the cell cycle (p,3.5610
26) and several important
signaling pathways from DAVID. While such hub genes were
clearly related to cancer, we hardly would have identified them by
analyzing differentially expressed genes or copy number alter-
ations alone, demonstrating that the pathway-based approach
considerably helped us to uncover these important players.
Utilizing DAVID, we also found that our target gene set was
enriched with genes in the cell cycle (p,7.6610
24), p53 signaling
pathway (p,9.1610
24), and RB Tumor Suppressor/Checkpoint
Signaling in response to DNA damage (p,4.8610
23). Among
target genes, we also found up-regulated WEE1, a tyrosine kinase
that phosphorylates CDK1 [27], a signaling event that is crucial for
the cyclin-dependent passage of various cell cycle checkpoints.
Previous reports suggested that overexpression of WEE1 is critical
for the viability of some cancertypes, andcelllines displaying higher
expression levels of WEE1 are sensitive to WEE1 inhibition [28].
Table 1. Functional analysis of genes selected in each step.
A. Number of Genes B. AceView (GBM) C. DAVID (Glioma)
Genome-wide association analysis 16056 0.56 (75) 0.027 (56)
Genome-wide association analysis + Bonferroni correction 1026 0.0029 (12) None
Circuit flow algorithm 701 0.045 (10) 1.3610
210 (25)
Circuit flow + Bonferroni correction 280 0.17 (4) 1.4610
27(16)
Circuit flow + set cover 128 4.7610
24 (6) 4.6610
24 (8)
(A) To determine the statistical significance of selected genes, we counted the number of genes identified in each step of our analysis. (B) Utilizing a set of 93 genes that
are implicated in GBMs as of Aceview we calculated the statistical significance of the overlap (numbers in parentheses) with a hypergeometric distribution. We found
that the significance increased, applying the steps in our approach. (C) Calculating p-values with a modified Fisher’s exact test, we obtained a similar result for a set of
glioma genes as of DAVID as well.
doi:10.1371/journal.pcbi.1001095.t001
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node on a path leading to a target gene must be a transcription
factor. With this change, we selected parameters in our multiset-
cover approach to obtain an alternative set with approximately the
same number of target genes and we found that it was almost
disjoint from our original set of 74 target genes (Fig. 3A). Despite
these differences, the final sets of causal genes had a strong overlap
(Fig. 3B) of 58 genes that we found in both sets. Such a level of
robustness is consistent with a pathway-centric view of complex
diseases: different sets of target genes are bundled within dys-
regulated pathways that are influenced by specific combinations of
causal genes. Even though the two target gene sets looked largely
different, both sets include genes that are differentially expressed in
the disease cases. In addition, we found that the genes are close
relatives in the network: the average distance between the two sets
of target genes is 1.7 (p=1.7610
212), suggesting that the genes
were selected from the same dysregulated pathways.
Chromosomal Analysis of Causal Genes
In Fig. 4A, we show the profile of genomic alterations in GBM
where we observed large areas of genomic amplification on
chromosome 7 and deletions on chromosome 10 (upper panel),
alterations that coincided with the genomic locations of EGFR and
PTEN. We located the genomic position of our 128 causal genes
and counted the number of corresponding target genes. We largely
observed that causal genes on chromosome 7 and 10 were strongly
connected to target genes, a pattern that strongly coincided with
the signature alterations of GBMs.
Since a target and a causal gene might be located on different
chromosomes, we determined the occurrences of such chromo-
some combinations using all target-causal pairs. Constructing such
a matrix (Fig. 4B) we found that strong causal signals emerged
from chromosomes 7 and 10. In turn, we observed that target
genes fell into three large clusters. In particular, target genes on
chromosomes 2, 3, 6, 10, 11, 12, 19 and 20 appeared to have
numerous links to causal genes located on chromosomes 7 and 10.
Focusing on target and causal genes in these areas, we found a
large cluster (box, Fig. 4C) of up-regulated genes that were
connected to an array of largely down-regulated causal genes.
Literature-Based Validation of Individual Causal Genes
In addition, we also looked for literature-based validation of
other causal genes. In particular we found RHOBOTB2, a
recently discovered tumor suppressor gene [29], in our set of 128
causal genes. We observed that this gene lacked a strong genomic
alteration signal, suggesting that our approach was also capable of
discovering a subtle causal signature that may have been otherwise
missed with a simple disease association analysis. We also found
some causal genes with strong genomic alterations that, although
not included in AceView nor in DAVID, are well known to be
associated with cancer. For example, our final causal gene set
included GBAS (for its causal network, see Text S1), a gene that
was reported amplified in more than 40% of glioblastomas [30,31]
and CEBPA (enhancer binding protein) that was amplified in
about 10% of leukemia cases [32].
Dysregulated Pathways and Subnetworks
We obtained 128 causal subnetworks from causal genes to their
target genes (see identifying dysregulated pathways section in
Materials and Methods). For each causal subnetwork, we
performed an enrichment analysis of GO-annotated biological
processes. Due to the hierarchical structure of GO terms, results
included many redundant terms, and general terms tend to have
more hits. In Table 3, we listed the most specific GO-annotated
biological processes with which more than one subnetworks are
enriched. For the full list, see Table S3. In Supplementary Dataset
S1 we provided a cytoscape file that allows an interactive
exploration of enrichment in the GO hierarchy. The frequently
enriched GO processes included several classical cancer-related
pathways. For example, 9 causal subnetworks are enriched with
epidermal growth factor receptor signaling pathway that has anti-
apoptotic properties and may enhance proliferation, invasion, and
migration of glioma cells [33,34,35]. Similarly, 6 causal-target
relationships affected the Insulin signaling pathway. Indeed, recent
reports provide an additional evidence for the role of this pathway
in glioblastoma [36], supporting the hypothesis that alterations in
different genes may dysregulate the same pathways and cause the
same disease. Other less frequent pathways were positive
regulation of MAP kinase activity, regulation of nitric-oxide
synthase activity, estrogen receptor signaling pathway, JAK-STAT
cascade and the regulation of transforming growth factor-beta2
Table 2. Functional analysis of final causal genes.
P-value Genes
Glioma 0.008 PRKCA,EGFR,AKT1,CDKN2A,CAMK2G,TP53,RB1,PTEN
Cell cycle 0.028 MCM7,CDKN2A,CDC2,TP53,ORC5L,RB1,ATR,BUB3,CUL1
p53 signaling pathway 0.030 CDKN2A,CDC2,TP53,ATR,FAS,THBS1,PTEN
Proteasome 0.026 PSMA1,PSMC6,PSMB1,PSMC3,PSMA5,PSMA4
Analyzing the enrichment in different functional gene sets provided by DAVID with a modified Fisher’s exact test, we found that our final set of 128 causal genes was
significantly overlapping with a set of glioma, cell cycle, p53 signaling and proteasome genes.
doi:10.1371/journal.pcbi.1001095.t002
Figure 3. The overlap of two different sets of causal/target
genes. In the Venn-diagram in (A) we show the overlap of two
different sets of target genes. Even though these sets were almost
disjoint, we found in (B) that the corresponding sets of their causal
genes overlapped by up to 45%. Even though the initial sets of target
genes were hardly similar, we concluded that our method remarkably
compensated this disparity by determining strongly overlapping sets of
causal genes.
doi:10.1371/journal.pcbi.1001095.g003
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(TGFB2) is known to be an important modulator of glioma
invasion [37,38]. Of particular interest is also a related SMAD
pathway that occurred in two of our causal subnetworks. While it
is debated if this pathway plays a role in TGF b-promoted
oncogenesis, a recent study indicated that SMAD-dependent
signaling through the induction of PDGF-B has a proliferative and
oncogenic role in glioma [39], which is in line with the presence of
SMAD genes in our causal subnetworks.
Testing if these GO-processes were enriched in the set of target
genes, we only found an enrichment of a small number of very
general, mostly cell-cycle related pathways (see Table S4 for the
complete list). Only one term ‘‘G1/S transition of mitotic cell
cycle’’ overlapped with the list of most specific terms discovered
through the analysis with flow-based causal paths. The lack of
specific terms in the GO analysis using target genes was expected
since target genes were sampled from multiple dys-regulated
pathways, therefore not leading to significant enrichment of
specific pathways.
We took a closer look at paths involving PTEN and EGFR. In
Fig. 5, we show a subnet of dysregulated pathways with PTEN as a
causal gene. We observed that the influence PTEN might exert on
target genes was largely mediated by prominent transcription
factors, such as TP53, MYC and MYB. Compared to pathways
from DAVID [25,26], this small network of causal paths was
enriched with cell cycle genes (p,0.003) and glioma genes
(p,0.02) as well as various types of cancer genes. As their causal
roles are indicated in Fig. 4C, we observed that PTEN and CDC2
(see Text S1) might exert their influence on the expression of
WEE1 through transcription factors TP53 and E2F4. Since CDC2
codes for CDK1, which is phosphorylated by WEE1 [27] , our
results suggest a feedback loop that might be important for cancer.
Figure 4. Chromosomal analysis of causal genes. (A) In the upper panel, we show the profile of genomic alterations in glioblastomas, where
we observed large areas of genomic amplification on chromosome 7 and deletions on chromosome 10. Utilizing predictions of causal genes, we
observe that the profile in the lower panel of occurrences (yellow bars) coincide well with the profile of alterations in the upper panel. Focusing on
causal genes in the final set-cover (green bars), we recover the initial patterns. In (B), we constructed a matrix, showing the number of pairs of target
and causal genes on their corresponding chromosomes. We found that causal genes on chromosomes 7 and 10 have numerous links to target genes
on chromosomes 2, 3, 6, 10, 11, 12, 19 and 20 (boxed area). (C) Focusing on target genes in these chromosomal areas, we marked the presence of a
causal path through a molecular interaction network between a target and causal gene as peach in the heat map. While bars indicated the
differential expression of the corresponding genes (green: down, red: up), we found a large cluster of up-regulated target genes that were regulated
by an array of largely down-regulated causal genes (boxed area).
doi:10.1371/journal.pcbi.1001095.g004
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both a target and causal gene. The considerable amplifications of
chromosome 7 make EGFR a strong candidate for a causal gene.
Indeed, we found causal paths that connected EGFR to a few target
genes (Fig. 6A). However, we also found a rather large number of
causal genes that regulated the expression of EGFR as a target gene
(Fig. 6B). Such observations suggest that EGFR might play a dual
role as a driver of changed gene expression as well as integrator of
causal molecular information from other genomic sites. Indeed, we
found numerous disease cases where EGFR was over-expressed
without alterations in its genomic location. Instead, we observed
that there exist a number of potential causal genes of EGFR with
copy number alterations such as ANXA11, CDKN2A, CHUK,
PTEN, IFNA4 and ZNF107 among others. Utilizing pathway
information from DAVID, we found that the subnet with EGFR as
a target gene was highly enriched with glioma genes (p,0.004), the
MAPK signaling pathway (p,0.02), and pathways in cancer in
general (p,8610
28).
Discussion
Integrating phenotypic, genomic and interaction data, we
introduced a novel approach for the simultaneous identification
of causal disease genes and dys-regulated pathways. Such causal
genes may include potential drivers of a tumor’s emergence as well
as potential drug targets. After selecting target genes that covered
the underlying disease cases, we determined associations between
altered genomic loci and changed expression levels of target genes
by a simple eQTL analysis. The key idea of our approach is to
combine evidence from association analysis with evidence from
pathway analysis. We also demonstrated the power of graph-
theoretical approaches in the selection of gene sets and
determination of cause-target relationships. Indeed, set cover
approaches are increasingly recognized as appropriate tools for
selecting disease genes [16,40], while current flow approaches or
equivalent random walk models have been successfully used for
modeling of information flow in biological and social networks
[41,42,43].
Adopting a current flow algorithm, we combined gene
expression and molecular interaction data to determine causal
paths through interaction networks. This approach allowed for
preferential use of network paths supported by expression data,
bypassing potential problems of pure topology based methods such
as shortest paths that treat all edges equally. Namely, the
assignment of resistance to network edges pushed electric current
preferentially through nodes that were expression-correlated with
the target genes. However, our method also tolerates a fraction of
non-correlated nodes, balancing the impact of network connec-
tions and a strongly varying degree of gene expression correlation
of nodes in the paths.
Current networks of protein interactions, protein-DNA inter-
actions and phosphorylation events are incomplete and noisy. In
addition, transcription factors for many genes are unknown, a
shortcoming that certainly affected the completeness of our results.
However, the problem is alleviated by the fact that cancer is
considered as a disease of pathways, suggesting that there exist
many ways of selecting a representative set of target genes that
represent dys-regulated pathways. Considering a cluster of
neighboring genes that participate in the same pathway, any
member of the cluster might serve as a target gene to uncover
causal genes dys-regulating the underlying pathway. We found
that the choice of different target genes provided robust results,
diminishing the effects of incomplete data.
We used linear regression for associations to take advantage of
its simplicity. To capture the complex relationship of copy number
and gene expression more accurately, other non-linear methods
can also be considered. However, little is currently known about
the precise impact of gene copy number variations on gene
expression levels in model organisms, a problem that might even
be aggravated by the presence of potential epistatic interactions
between loci. In our approach, we alleviated such problems by
adopting a relatively liberal p-value cut-off in the initial step of the
algorithm. To compensate for this choice, we augmented genome-
wide associations with putative paths through a network of
molecular interactions. This step allowed us to filter spurious
associations and simultaneously uncover other molecules that
participate- in the propagation of the perturbation.
Being based on high-throughput interaction data, our approach
does not allow us to propose specific molecular mechanisms of
signal propagation at this point. Although our method provides an
Table 3. Enrichment of GO biological processes in causal
subnetworks.
GO biological process #
cell cycle arrest 10
epidermal growth factor receptor signaling pathway 9
negative regulation of cell growth 9
Ras protein signal transduction 9
regulation of sequestering of triglyceride 8
cell proliferation 7
nuclear mRNA splicing, via spliceosome 7
regulation of cholesterol storage 7
nucleotide-excision repair 7
RNA elongation from RNA polymerase II promoter 7
insulin receptor signaling pathway 6
transcription initiation from RNA polymerase II promoter 6
N-terminal peptidyl-lysine acetylation 5
phosphoinositide-mediated signaling 5
positive regulation of lipid storage 4
positive regulation of specific transcription from
RNA polymerase II promoter
3
positive regulation of epithelial cell proliferation 3
base-excision repair 2
negative regulation of hydrolase activity 2
gland development 2
positive regulation of MAP kinase activity 2
regulation of nitric-oxide synthase activity 2
estrogen receptor signaling pathway 2
regulation of receptor biosynthetic process 2
response to organic substance 2
JAK-STAT cascade 2
regulation of transforming growth factor-beta2 production 2
G1/S transition of mitotic cell cycle 2
SMAD protein nuclear translocation 2
For each of 128 causal subnets, we determined the enrichment of biological
processes as annotated in GO (corrected p-value ,0.05, Boferroni corrected).
Counting the number of occurrences of each process in the causal
subnetworks, we listed the most specific GO annotated biological processes that
appeared enriched in at least 2 subnetworks.
doi:10.1371/journal.pcbi.1001095.t003
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observed associations, uncovered pathways should be considered
testable hypotheses rather than ultimate and mechanistic proofs of
causal relationships.
The augmentation of associated gene-loci pairs with pathway
information resulted in a very powerful strategy, allowing us to not
only uncover potential causal genes, but also find intermediate
nodes on molecular network paths that mediated information
Figure 6. The network of causal paths from and to EGFR. In (A) we show a network of causal paths that included EGFR as a causal gene. While
this network was rather small, we found a large network of causal paths where EGFR was a target gene in (B). Specifically, we observed that EGFR
might be influenced by numerous causal genes through prominent transcription factors.
doi:10.1371/journal.pcbi.1001095.g006
Figure 5. The network of causal paths from PTEN. We observed that PTEN might exert its influence on target genes (the endpoints of each
causal path) through prominent transcription factors such as TP53, MYC and MYB.
doi:10.1371/journal.pcbi.1001095.g005
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identified functional GO-pathways that mediate many genotype -
phenotype associations in GBM. In addition to identifying putative
causal genes and dys-regulated functional pathways, our approach
provided evidences for the pathway-centric perspective of complex
diseases. Firstly, we showed that various genetic perturbations lead
to dys-regulation of the same functional pathways. Furthermore,
consistent with the hypothesis that genotypic variations dys-
regulate whole pathways rather than target individual genes, we
found that different sets of target genes sampled from the same
pathways lead to uncovering the same causal genotypic variations.
Our method consists of multiple steps of analyses. However, each
individual step can be used separately, depending on a specific
application. For example, in the first step we selected a set of
differentially expressed genes in cancer as target genes. However,
this set can be replaced with other user selected set of interest,
therefore facilitating targeted studies of particular pathways.
To our best knowledge, our method is the first genome-wide
computational approach that reached beyond a simple association
analysis. In addition, our method supported genome-wide
associations by paths through interaction networks that can, in
principle, propagate the information flow from causal genes to
target genes. While copy number variation and gene expression
data of glioblastoma patients provided an opportunity to test our
approach, our method can be applied to any disease system where
genetic variations play a fundamental, causal role.
Materials and Methods
mRNA Data Treatment
We utilized 158 patient and 32 non-tumor control samples
collected from the NCI-sponsored Glioma Molecular Diagnostic
Initiative (GMDI) [44,45] which were profiled using HG-U133
Plus 2.0 arrays. Arrays were normalized at the PM and MM probe
level with dChip [44,46]. Using the average difference model to
compute expression values, model-based expression levels were
calculated with normalized probe level data. Negative average
differences (MM . PM) were set to 0 after log-transforming
expression values [44]. Accounting for weak signal intensities, all
probesets with more than 10% of zero log-transformed expression
values were removed. To represent a gene, we chose the
corresponding probeset with the highest mean intensity in the
tumor and control samples. Gene expression profiles are available
through the Rembrandt database (http://rembrandt.nci.nih.gov/).
Determination of Copy Number Alterations
All patient and non-tumor control samples were hybridized on
the Genechip Human Mapping 100K arrays, and copy numbers
were calculated using Affymetrix Copy Number Analysis Tool
(CNAT 4). After probe-level normalization and summarization,
calculated log2-tranformed ratios were used to estimate raw copy
numbers. Using a Gaussian approach, raw SNP profiles were
smoothed (.500 kb window by default) and segmented using a
Hidden Markov Model approach [45,47,48]. Genomic alteration
profiles are available through the Rembrandt database (http://
rembrandt.nci.nih.gov/).
Considering alterations of copy numbers (CN), we defined an
amplification if log2 CN - 1.0.1 and a deletion if log2 CN -
1,20.1.
Interaction Network
We utilized human protein-protein interaction data from large-
scale high-throughput screens [49,50,51] and several interaction
databases [52,53,54,55] totaling 93,178 interactions among 11,691
genes. As a reliable source of experimentally confirmed protein-
DNA interactions, we used 6,669 interactions between 2,822
transcription factors and structural genes from the TRED
database [56]. As for phosphorylation events between kinases
and other proteins we used 5,462 interactions between 1,707
human proteins from the networKIN [57,58] and phosphoELM
database [59]. Pooling all interactions we obtained a network of
11,969 human proteins that are connected by 103,966 links.
Selection of Target Genes
We identified genes that are differentially expressed in the
disease cases compared to the non-disease controls in each case.
Specifically, we normalized gene expression values as a Z-score,
utilizing mean and standard deviation of gene expression values in
the non-disease control cases. We considered a gene differentially
expressed if the normalized gene expression value of the gene had
a p-value ,0.01 in the given case using a Z-test.
We chose a representative set of target genes by formulating the
problem as a minimum multi-set cover. First, we defined a
bipartite graph B(T, S) between genes T and disease cases S by
adding edges between genes g and cases s if and only if gene g was
differentially expressed in case s. We constructed a multi-set cover
instance SC ={ B(T, S),a, b} where a represented the number of
times that a case needed to be covered, and b was the maximum
number of outliers. In other words, all but b cases needed to be
covered at least a times in the output cover. The problem to
choose a minimum number of genes, satisfying the constraints is
NP-hard (i.e., computationally not feasible), prompting us to design
a greedy algorithm. The pseudocode of the corresponding
algorithm is shown in the Text S1. We demanded that a case
needed to be covered at least a =55 times with a maximum of
b =3 outliers, obtaining 74 target genes.
eQTL Mapping
We utilized a set of loci L ={ l1,l 2,…, lm} where each locus li
was characterized by the corresponding copy number cni,j in each
case j, CNi ={ cni,1,c n i,2,…, cni,n}. Since copy numbers of nearby
loci tend to be highly correlated we significantly reduced the
number of loci by a local clustering. Specifically, for a potential tag
locus tlk, we greedily accumulated all consecutive loci, ensuring
that the Pearson’s correlation coefficient of CNk and CNi at any
locus li in the region was . hTL =0.9. Tag loci and associated
regions can be computed in time linear to the number of loci.
Note, that adjacent regions may overlap and a gene may belong to
more than one region. Given a set of tag loci TL ={ tl1,t l 2,…, tlm},
we identified candidate causal loci by associating copy number
alterations with expression profiles of target genes. Given a set of
target genes TG and tag loci TL, we calculated significant
associations by a linear regression between the normalized
expression values of gene tgi, E(tgi), and copy numbers of tag locus
tlj, CN(tlj). For each target gene tgi, TL i ðÞ (TLincluded all tag loci
with p,0.01. We considered a tag loci tlj associated with tgi if tlj [
TL(i).The pseudocode for selecting tag loci and eQTL mapping is
presented in the Text S1.
Solution of the Electric Circuit Problem
The circuit flow algorithm is based on the well-known analogy
between random walks and electronic networks where the amount
of current entering a node or an edge in the network is
proportional to the expected number of times a random walker
will visit the node or edge. Let G=(N, E) represent a gene
network where N is a set of genes and E is a set of molecular
interactions. Let vector I =[ I(e) for e M E] denote current passing
through the edges, and vector V =[ V(n) for n M N] holds variables
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candidate genes located in its genomic region. Vector X =[ X[c]
for c M C] denotes the current leaving the candidate genes. For an
edge e =(u,v) connecting genes u and v, we calculated the gene
expression correlations corr(u, tg) and corr(v, tg) between both genes
and target gene tg. We defined the conductance of edge e, w(e) as
the mean of corr(u, tg) and corr(v, tg). As such, we ensured that a
single non-correlated node reduced but not completely interrupted
the current flow, while a cluster of non-correlated nodes put a
considerable resistance to the current flow. Ohm’s law is defined as
Id|IzP|V~0 ð1Þ
where Id is an |E|6|E| identity matrix, and O is a zero matrix. P
is an |E| 6|N| matrix and P(e, n)=w(e)i fn=v , -w(e)i fn=u ,
and 0 otherwise. Kirchhoff’s current law is
Q|IzR|X~T ð2Þ
where Q is an |N| 6|E| matrix, and Q(n, e)=1i fn=u , 21i f
n=v , and 0 otherwise. R is an |N|6|C| matrix where R(n, c)=1
if n=c ,and 0 otherwise. T is an |N|61 vector where T(n)=1i f
n is the target gene tg, and 0 otherwise.
Finally, we set the voltage of all genes in C to be 0 so that all
current flowed into the candidate genes and there is no current
flow between candidate genes, defined as
S|V~0 ð3Þ
where S is a |C|6|N| matrix and S(c, n)= 1i fn=c ,and 0
otherwise.
The set-up of such a linear system implicitly considered all
interactions undirected and stipulated that each interaction can
have a regulatory effect on the expression of a target gene. In order
to obtain more biologically meaningful results, we demanded that
direct regulation activity on the expression of target genes is
mediated by transcription factors. Therefore, we determined paths
where target genes interacted with transcription factors only. In
addition, we also accounted for directions of protein-DNA
interactions and phosphorylation events. Since linear program-
ming approaches to solve such a directed model [21] required
extreme computational resources, we implemented a simple
heuristic: after solving the linear system, we removed edges that
were used in the wrong direction. We repeated this procedure until
only a small number of directed edges were used in the wrong
direction (see Text S1 for details). We chose a threshold of 100,
which was approximately 0.1% of the total number of edges and
found that this heuristic provided a reasonable approximation to
the linear programming approach.
Empirical P-Values
Since the number of genes located in each region varied from 0
to several hundreds, the amount of current that flows to genes
cannot be compared directly among different loci to prioritize
genes. Given the results of the circuit flow algorithm, an empirical
p-value for each pair of a target and a causal gene was estimated,
utilizing 30 random networks. Random networks were generated
by swapping edges while preserving node degrees to avoid
potential biases toward hub nodes. Assuming that each edge had
a unit conductance, we ran the circuit flow algorithm in each
random network for the same set of genes and computed the
amount of current flowing into each gene located in the tag locus.
A normal distribution was fitted to the current values in the
random networks, and empirical p-values were computed using a
Z-test.
For each locus and a set of genes in the associated region, we
only considered genes receiving current of at least 70% of the
maximum current among all genes in the region. Utilizing the
permutation method, we selected candidate causal genes for each
target gene if the empirical, gene specific p,0.05. On average, we
found a total of 701 causal genes for all 74 target genes (for details
of parameter settings, please see Text S1).
Identifying Dysregulated Pathways
Let region(cg) be the region that contains a causal gene cg. Recall
that regions may overlap, and therefore a gene can be part of more
than one region. Let regionmax(cg, tg) and tlmax(cg, tg) be the region and
tag locus that harbored causal gene cg and have the most
significant p-value among all the current flow solutions from a
target gene tg to regions in region(cg). Utilizing a current flow
solution Sol(tg, tlmax(cg, tg)) from tg to tlmax(cg, tg), we first removed any
nodes with empirical p-value .0.05 from the network. Subse-
quently, we determined a maximum current path from tg to cg
which was defined as a simple path P (tg, cg)=( tg, g1,g 2,…, cg) such
that mingi[P(tg,cg)I(gi) was maximized where I(gi) was the total
current passing through the gene gi (please see Text S1 for
algorithmic details). We computed a path for each pair of a final
causal gene and a target gene affected by the causal gene.
Selecting a Final Set of Causal Genes
One of our primary goals was to identify a set of causal genes
that explains (almost) all disease cases. Given a set of candidate
causal genes and their corresponding copy number variations we
identified a subset of common causal genes that explains the
disease cases. Specifically, a causal gene cgk explains a case si if (i)
the tag locus including the gene has copy number alterations in
case si and (ii) there exists a nonempty set of target gene(s), TG(cgk,
si), which are affected by cgk (i.e., with P,0.05) and differentially
expressed in case si. The weight between a causal gene and a case,
w(k,j) is defined as w(k,j) = |TG(cgk,s i)|.
A weighted bipartite graph WB(C, S) between a set of candidate
causal genes C and disease cases S can be constructed by adding
edges between gene cgk and case si if and only if gene cgk explains a
case si. For a subset of candidate causal genes C0 and a case s, let
W(C0,s ) be the total number of target genes covering s by the
genes in C0, W(C0,s)~D
S
c[C0 TG(c,s)D. We considered a case as
explained if the total weight covering the case exceeds a certain
threshold. As in the preprocessing in the first step, we wanted to
explain all cases (allowing a few outliers) with minimum number of
causal genes (Fig. 1D). The problem can be formulated as a
variant of minimum weighted multi-set cover problem. Consider an
instance WSC ={ WB(C, S), c, d} where WB(C, S) is a weighted
bipartite graph between causal genes C and cases S. We wanted to
choose a subset of genes C’ from C such that for each case s except
d cases, W(C’, s) $ c. Since a very simple version of the multi-set
cover problem (unweighted without outliers) is NP-hard, we
designed an algorithm, using a greedy approach to choose a subset
of causal genes. Repeatedly, we computed the total weight that can
be covered by choosing a gene and selected a gene with maximum
additional total weight until the constraints are satisfied (See Text
S1 for algorithmic details). Recall that target genes were chosen so
that each disease case (except 3 cases) had at least 55 target genes
in the first step. As some target genes may not cover the same
disease case due to the stricter definition in this step, we found that
d=21 disease cases had less than 50 target genes covering the
cases. Therefore, we required an accumulated weight between the
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cases and selected 128 final causal genes.
Computational Costs
The computationally most expensive component in our
algorithm was the circuit flow algorithm. Due to the large size
of the human molecular interaction network and the large number
of potential causal loci per target gene, the approach required
significant computational resources to find a solution to the circuit
flow problem and calculate empirical p-values using a permutation
method. On average, it took approximately 60-80 hours per target
gene to compute solutions for all associated loci (including
permutation tests). We used the computing cluster at the NCBI
for our computations, allowing us to run several dozens of
computations in parallel. In addition, we adapted various
optimization techniques to expedite the procedure [60].
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